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Abstract 
 
PURPOSE: To investigate the progression of vascular lesions of polypoidal choroidal 
vasculopathy (PCV) as viewed with indocyanine green angiography, and visual 
prognosis of these eyes. 5 
DESIGN: Retrospective case study. 
METHODS: We reviewed retrospectively the medical records of 88 consecutive patients 
(88 eyes) with PCV that had been examined with indocyanine green angiography for 
more than 2 years. 
RESULTS: Depending on the initial area of the vascular lesion, eyes were divided into 10 
smaller PCV (baseline area of lesion being < 1 disc area [DA], n = 22) and larger PCV 
(baseline area of lesion being > 1 DA, n = 66). In larger PCV, the mean area of the lesion 
progressed significantly from 6.49 ± 8.96 mm2 to 16.27± 14.19 mm2 (P < .0001) with 
marked deterioration of visual acuity (P < .0001) during follow-up. In contrast, smaller 
PCV often showed minimal progression of the lesion, only limited exudative change, and 15 
the eyes maintained their initially good vision to the final visit. Smaller PCV lesions rarely 
progressed to extensive PCV lesions. Severe vision threatening complications (i.e., 
suprachoroidal hemorrhage, vitreous hemorrhage, and tears of the retinal pigment 
epithelium) were seen only in eyes with larger PCV, and in studying SNPs A69S of 
ARMS2 genes, there was a significant difference in T allele frequency between 20 
individuals with smaller PCV and those with larger PCV (20.2% vs 79.8%, P = .0235). 
CONCLUSIONS: PCV with small vascular lesions shows minimal progression and no 
vision threatening complications, and these eyes often maintain good visual acuity for a 
long time. 
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Polypoidal choroidal vasculopathy (PCV) was first described as a new clinical entity with 
a unique form of choroidal vascular abnormality,1-3 and is characterized by a branching 
vascular network that terminates in polypoidal lesions seen by indocyanine green 
angiography.4 Initially, vascular components of PCV are reported to be seen 
predominantly in a peripapillary location,5 but macular PCV6, 7 and peripheral PCV5, 8 5 
have since been reported. Yannuzzi and associates9 expanded the clinical spectrum of 
this disease and established the current understanding of PCV. Today, macular PCV is 
more common in Asian populations and seems to be the condition most clinically 
significant.7, 10, 11 To date, however, the pathogenesis of PCV is not fully understood, and 
it is still controversial as to whether or not it originates from an abnormality of the inner 10 
choroidal vessels or if it is a variant of choroidal neovascularization (CNV).12 
     PCV is accompanied often by recurrent serosanguineous detachments of the 
retinal pigment epithelium and neurosensory retina, and sometimes results in massive 
hemorrhagic complications with a sudden loss of vision.13, 14 While the extent of visual 
disturbance in PCV varies, it is generally thought that the visual prognosis of PCV is 15 
better than that of exudative age-related macular degeneration (AMD).11, 12 In a previous 
report by Uyama and associates,11 about half of the patients with PCV had a favorable 
visual outcome (better than 20/30) after being followed-up for more than 2 years. In PCV, 
other vision-threatening complications, such as type 2 CNV, disciform scar, or cystoid 
macular edema, are reported to be uncommon.10, 12 20 
     Clinically, the size of the vascular lesions in PCV varies.15 We sometimes see 
cases of PCV with a large lesion that show a poor response to the treatment and show 
progression of the lesion, resulting in poor visual prognosis. Tateiwa and associates16 
reported that PCV with a large vascular network that extends beyond the vascular 
arcade is not uncommon, so we might speculate that vascular lesions of originally small 25 


































































Lesion size of PCV. Tsujikawa, et al. Page 3 
this type of progression.17 PCV cases with a small lesion often show minimal exudative 
change and no progression of the lesion, and can maintain good visual function for a 
long time.18 Even with an exudative change, small PCV often show a favorable response 
to treatment.19 Okubo and associates18 reported that a reddish-orange nodule alone, or 
that multiple reddish-orange nodules with a small subretinal hemorrhage, is a sign of a 5 
potentially benign clinical course, so the clinical course of small and large PCV may be 
different. 
     In order to study the progression of vascular lesions in PCV, it is essential to 
perform repeated indocyanine green angiography,4 because most vascular lesions of 
PCV are located beneath the retinal pigment epithelium.1-3 So far, however, there is little 10 
information on the long-term observation of the vascular components of PCV.15 In the 
study described herein, we investigated progression of the vascular lesion of PCV using 
indocyanine green angiography and visual prognosis of affected eyes. Based on our 
findings, we report a new classification of PCV and the expected complications and 
visual prognosis of these two types of PCV. 15 
 
PATIENTS AND METHODS 
For this observational case study, we reviewed retrospectively the medical records of 88 
consecutive patients (88 eyes) with symptomatic PCV who initially visited the Macula 
Service of the Department of Ophthalmology at Kyoto University Hospital between 20 
January 2004 and October 2007, and who had been examined with both fluorescein and 
indocyanine green angiography for more than 2 years after their initial visit. When both 
eyes were diagnosed as having PCV, one eye was selected randomly for inclusion in the 
current study. 
     The diagnosis of PCV was based on indocyanine green angiography, which shows 25 
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lesion can be a single polyp or a cluster of multiple polyps. In most cases, the 
reddish-orange nodule that had been seen by the ophthalmoscopic examination 
corresponded to the polypoidal lesion. Eyes with other macular abnormalities (i.e., AMD, 
pathologic myopia, idiopathic CNV, presumed ocular histoplasmosis, angioid streaks, 
and other secondary CNV) were excluded from the current study. Eyes that were treated 5 
previously with focal laser photocoagulation, photodynamic therapy (PDT), vitrectomy, 
radiation therapy, or anti-vascular endothelial growth factor (VEGF) therapy were also 
excluded from the present study. 
     At the initial visit, all patients underwent a comprehensive ophthalmologic 
examination, including measurement of best-corrected visual acuity (VA), determination 10 
of intraocular pressure, indirect ophthalmoscopy, slitlamp biomicroscopy with a contact 
lens, and optical coherence tomography (OCT). After fundus photographs were taken, 
fluorescein and indocyanine green angiography were performed on each patient using a 
confocal laser scanning system (HRA-2, Heidelberg Engineering, Dossenheim, 
Germany). In all patients, VA measurement and OCT examination were performed at 15 
each follow-up visit. At follow-up visits, angiography was performed if necessary, 
although all patients in the current study were examined with angiography several times 
during their follow-up. In the study described herein, the angiograms obtained at the 
initial visit were compared with the final angiograms. 
     In the current study, greatest linear dimension and area of the lesion were 20 
determined based on the indocyanine green angiography, using the software built into 
the HRA-2 machine. Greatest linear dimension included the entire PCV vascular lesion, 
including polypoidal lesion, branching vascular network vessels, and any type 2 CNV. 
The area of the vascular lesion was measured manually with the software that came with 
the HRA-2. The pigment epithelial detachment, without underlying vascular components, 25 
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In the current study, one optic-disc area (DA) is equal to 2.54 mm2, on the basis of one 
optic disc diameter being equal to 1.8 mm. Based on the area of the lesion at the initial 
visit, we classified the eyes into either the smaller PCV group (baseline area of lesion < 1 
DA) or the larger PCV group (baseline area of lesion > 1 DA) in order to compare the 
clinical course of the two groups. 5 
     We also compared the initial OCT measurement and VA with values obtained at 
the final visit. To compare the difference in VA, VA measured with a Landolt chart was 
converted to a logarithm of the minimal angle of resolution (logMAR). Using OCT images, 
we performed two measurements (foveal thickness, and thickness of the neurosensory 
retina in the fovea) with a caliper that was built into the software of the OCT machine. 10 
Foveal thickness was defined as the distance between the vitreoretinal interface and the 
retinal pigment epithelium; thickness of the neurosensory retina was defined as the 
distance between the vitreoretinal interface and the tip the outer segment of the inner 
and outer segments of the photoreceptors. 
     We genotyped the major AMD and PCV-associated SNP, rs10490924 (A69S), of 15 
ARMS2. Genomic DNA was prepared from leukocytes of peripheral blood using a DNA 
extraction kit (QuickGene-610L, Fujifilm, Minato, Tokyo, Japan). The SNPs were 
genotyped using Taqman SNP assays with the ABI PRISM 7700 system (Applied 
Biosystems, Foster City, California) according to the manufacturer’s instructions. 
     Statistical analysis was performed using software designed for this purpose 20 
(StatView, version 5.0; SAS Institute, Cary, North Carolina). A P value of less than 0.05 
was considered to be statistically significant. 
 
RESULTS 
In the current study, 88 eyes of 88 patients (60 men and 28 women) with PCV, ranging in 25 
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from 29 to 61 months (46.4 ± 8.6 months), and duration from the initial angiogram to the 
last ranged from 24 to 60 months (39.3 ± 9.4 months). All patients were examined with 
fluorescein and indocyanine green angiography repeatedly during follow-up, ranging 
from 2 to 11 times (4.9 ± 2.0 times). Table 1 shows the characteristics of patients eligible 
for inclusion in this study. The mean baseline VA (logMAR) was 0.37 ± 0.34. The mean 5 
initial area of the lesion and greatest linear dimension was 7.75 ± 9.78 mm2 and 3412 ± 
1647μm, respectively. Figure 1 shows the relationship between area of the lesion, 
greatest linear dimension, foveal thickness, and VA at initial visit and final examination. 
Initial area of the lesion (R = 0.801, P < .0001) and initial greatest linear dimension (R = 
0.805, P < .0001) showed a close correlation with final measurements. 10 
     PCV vascular lesion at the initial visit varied in size, ranging from 0.64 to 63.82 
mm2. Depending on the initial area of the lesion, we divided the eyes with PCV into two 
groups—the smaller PCV group (baseline area of lesion being < 1 DA, n = 22) and the 
larger PCV group (baseline area of lesion being > 1 DA, n = 66) (Figure 2). The mean 
area of the lesion was initially 1.68 ± 0.53 mm2 in the smaller PCV group and 9.79 ± 15 
10.55 mm2 in the larger PCV group. There were no significant differences in gender, age, 
or duration of symptoms between groups (P = .5971, P = .3257, and P = .6484, 
respectively). In addition, there were no differences in the foveal thickness (P = .4628) or 
thickness of the neurosensory retina in the fovea (P = .4204) at the initial visit. However, 
the initial VA was significantly better in eyes with smaller PCV (0.24 ± 0.39) than in eyes 20 
with larger PCV (0.42 ± 0.35, P = .0383). 
     During the follow-up period, 64 eyes were treated initially with PDT, and 9 were 
treated initially with anti-VEGF therapy. In spite of these treatments, some eyes with 
larger PCV showed extension of the vascular component with an exudative change. The 
mean area of the lesion in larger PCV progressed significantly from 9.79 ± 10.55 mm2 to 25 
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these eyes deteriorated significantly 0.42 ± 0.35 to 0.76 ± 0.49 at the final examination 
(P < .0001). In contrast, eyes with smaller PCV lesions often showed minimal 
progression of the lesion and limited exudative change, and smaller PCV lesions rarely 
progressed to extensive PCV lesions (Figure 4). However, even in eyes with smaller 
PCV, the mean lesion size increased during the follow-up period (P = .0037). In smaller 5 
PCV, change in area of the lesion and final area of the lesion were 2.45 ± 3.53 mm2 and 
4.13 ± 3.59 mm2, respectively, which were significantly less than those of the larger PCV 
(P = .0429 and P = .0002, respectively). In addition, eyes with the smaller PCV showed 
no decrease in VA (-0.05 ± 0.36, P = .5492), and maintained initial VA to the final visit; 
mean changes in VA were significantly better in smaller PCV than were those in larger 10 
PCV (P = .0015). 
     Table 2 shows the ocular manifestations and complications seen during follow-up 
in eyes with smaller or larger PCV. Of the 88 eyes included, seven (7.6%) showed 
suprachoroidal hemorrhage and eight (8.7%) showed vitreous hemorrhage (Figure 5), 
all of which were seen in eyes with larger PCV; no eyes with smaller PCV showed 15 
severe complications (P = .1111 and P = .0868). Indeed, in eyes with smaller PCV, even 
the relatively small amount of subretinal hemorrhage noted (> 1 DA) was seen less 
frequently than in eyes with larger PCV (P = .0157). In addition, other ocular 
manifestations associated with severe visual disturbance were seen more often in eyes 
with larger PCV. Type 2 CNV, subretinal fibrosis, and cystoid macular edema were seen 20 
more frequently in eyes with larger PCV (P = .0030, P = .0533, and P = .0266). Of the 88 
eyes included in this study, 41 (46.6%) showed a serosanguineous pigment epithelial 
detachment (area > 1 DA). Again, a pigment epithelial detachment was seen more 
frequently in eyes with larger PCV than in those with smaller PCV (P = .0096). Of the 88 
eyes of our patients, eight (8.7%) showed a tear of the retinal pigment epithelium. All of 25 
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= .0868). 
     We were able to examine the DNA of 76 of the 88 patients. Table 3 shows the 
distributions of ARMS2 (A69S) genotypes in patients with smaller PCV and in those with 
larger PCV. There was a significant difference in T allele frequency between patients 
with smaller PCV and those with larger PCV (20.2% vs 79.8%, P = .0235). In 5 
comparison to wild-type homozygosity (GG), homozygosity for the at-risk genotype (TT) 
increased the likelihood for the larger PCV group by 5.0-fold, and heterozygosity for the 
at-risk genotype (GT) increased the likelihood for this same group by 1.5-fold. 
 
DISCUSSION 10 
Based on the initial area of the vascular lesion, we defined smaller PCV as those with a 
baseline area of < 1 DA. The remaining PCV, in which the baseline area was > 1 DA, 
were defined as larger PCV. There were no significant differences in age or duration of 
symptoms between these two groups. The larger PCV did, however, often show 
progression of the vascular lesions, which in many instances showed an exudative 15 
change. In larger PCV, poor initial VA was even further lessened in spite of the treatment. 
In contrast, most eyes diagnosed as having smaller PCV showed only minimal 
progression of the lesion, and limited exudative change. Furthermore, smaller PCV 
lesions rarely progressed to extensive PCV lesions. Most eyes with smaller PCV had 
good initial VA, and maintained their good VA throughout the follow-up period. 20 
     In addition, severe complications such as suprachoroidal hemorrhage, vitreous 
hemorrhage, and a tear of the retinal pigment epithelium were seen only in eyes with 
larger PCV; no eyes with smaller PCV showed these severe complications. Furthermore, 
type 2 CNV and subfoveal fibrosis was seen more frequently in larger PCV. From these 
findings, we believe that the ocular manifestations, complications, and visual prognosis 25 
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similar findings. Of 13 eyes with PCV that were followed-up for 5 years or longer, with no 
treatment, they reported that eyes with reddish-orange nodules alone or those with 
nodules plus a small subretinal hemorrhage had a benign clinical course with stable 
vision.18 
     PCV is thought to have a better visual prognosis than does exudative AMD,9, 20 5 
although the visual prognosis in PCV is not as promising as was thought initially.21 
Previously, direct laser photocoagulation was applied to eyes with PCV.7, 22 Unless the 
entire vascular lesions could be coagulated, however, the polypoidal lesion often 
recurred, resulting in decreased VA,23 although another study showed encouraging 
short-term results of PDT for PCV.24 However, one or more years after initially successful 10 
treatment with PDT, some eyes had a recurrence of PCV and a decrease in VA.21 Still 
more recently, although anti-VEGF therapy can reduce the exudative change in PCV 
shortly after treatment, its effects on the vascular lesions and its effect on VA appear to 
be limited.25-29 In addition, some eyes with large vascular lesions show massive 
hemorrhagic complications, with sudden visual loss.30 As shown in Table 2, other 15 
vision-threatening complications, such as disciform scar, a tear of the retinal pigment 
epithelium, or cystoid macular edema, are not as uncommon as reported initially.16, 31, 32 
Smaller PCV, which often shows a favorable response to treatments and with minimal 
vision-threatening complications, turn out to have a better visual prognosis than do 
larger PCV.17, 18 20 
     So far, several classifications of PCV have been reported.11, 12 Based on the 
location of the lesion, PCV can be categorized as peripapillary, macular, or peripheral.12 
When the vascular lesion is located far from the fovea, visual prognosis tends to be 
good.5 Uyama and associates11 reported two patterns of fundus manifestation of PCV, 
exudative and hemorrhagic. However, they reported also that 36% of the cases had 25 
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might be difficult to predict visual prognosis. 
     The polypoidal lesions are thought to be the main source of the exudative change 
and hemorrhagic complications in PCV.4, 14 Uyama and associates11 reported two 
patterns of polypoidal lesions: solitary round aneurysmal dilations and a collection of 
small aneurysmal dilations that resemble a cluster of grapes, the latter of which is 5 
associated with a poor prognosis. Clinically, some polypoidal lesions do regress 
spontaneously, and regress even more after PDT, but these polypoidal lesions recur at 
the same location or at other terminals of the branching vascular network.9, 12, 33 Recently, 
Cackett and associates34 reported a classification system of PCV based on polypoidal 
lesion seen by indocyanine green angiography. In their report,34 PCV was classified 10 
according to size, location, formation, and number of polypoidal lesions. While objective 
evaluations are essential for any multicenter study, the branching vascular network, 
which is one origin of the polypoidal lesions, is essential also to understand status of the 
disease in each individual patient.35 
     Based of the observation by indocyanine green angiography, Yuzawa and 15 
associates36 reported that there may be two types of branching vascular network, one 
representing an intrachoroidal vascular abnormality, and the other representing 
neovascularization that grows rapidly in the subretinal pigment epithelial space.  
Unfortunately, histologic reports of PCV are limited,37, 38 although recent OCT findings 
support the theory that the vascular components of PCV are located intra- or 20 
supra-Bruch’s membrane. In Figure 4, both the polypoidal lesion and the branching 
vascular network are seen between the retinal pigment epithelium and Bruch’s 
membrane,39 suggesting that the vascular lesions in PCV are a form of CNV.14 
     The branching vascular network, which only rarely disappeared with treatment, 
tended to extend over time.35 It is thought that progression of PCV is slower than that of 25 
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enlarges by simple proliferation and hypertrophy of the vascular components, by 
conversion of the polypoidal lesion into the advancing edge of a vascular channel, or by 
the unfolding of a cluster of polypoidal lesions and subsequent transformation into 
enlarging vascular tubular components. In the current study, based on the initial size of 
the vascular components, we divided PCV into smaller and larger types, a classification 5 
that provides useful information to both physicians and patients on the risk of severe 
complications and on visual prognosis. Smaller PCV rarely progress to become 
extensive lesions, and often have a more favorable clinical course that is quite different 
from that of larger PCV.17, 18 In the current study, all 15 eyes that developed finally 
extensive vascular lesions (more than 8 DA) had the lesion of more than 3 DA at the 10 
initial examination. It follows that all eyes with extensive PCV had already shown 
relatively large vascular lesion when they had initial visual symptoms. From the current 
study, we could not provide any information on the beginning of the extensive PCV.  
     In the current study, we examined the genotypes of rs10490924 (A69S) of ARMS2 
in patients with smaller PCV (21 patients) and those with larger PCV (55 patients). An 15 
increasing number of reports showed that ARMS2 A69S is associated strongly with AMD, 
as well as with typical AMD and with PCV. 40-45 In the current study, there was a 
significant difference in T allele frequency between the smaller PCV and the larger PCV 
(20.2% vs 79.8%). Our findings suggest that smaller PCV is different from larger PCV, 
not only from the clinical point of view but also from the genetic point of view. 20 
     In PCV patients, Sakurada and associates40 reported a difference in the genotypic 
frequency at this site between eyes with and without vitreous hemorrhage, with the 
frequency of the T allele being significantly greater in the vitreous hemorrhage group 
than that in the non-vitreous hemorrhage group.40 In another report, Sakurada and 
associates46 reported that this genotype is not associated with lesion composition or size 25 
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at this SNP is associated with the exudative activity of polypoidal lesions.46 While further 
studies are necessary to elucidate the contribution of this SNP to the progression of the 
vascular lesion, this SNP appears to be associated with the occurrence of PCV itself and 
with activity of the vascular lesions. 
     Limitations of the current study are its retrospective nature and the various 5 
treatment regimens used. Our patents received primarily PDT or anti-VEGF therapy.25-29 
Because recent studies have suggested that PDT in combination with anti-VEGF 
therapy may be the most promising treatment of PCV, it is possible that our patients did 
not receive the most effective treatment.47, 48 In the current study, 8 eyes showed a 
relatively large subretinal hemorrhage at the initial visit. It may be possible that the lesion 10 
size was somewhat underestimated in a few eyes. However, because all of these eight 
eyes were classified as having larger PCV, there is no possibility that any eye with a 
relatively large subretinal hemorrhage was classified incorrectly as having a smaller 
PCV. In addition,11 of 22 eyes with smaller PCV still had small lesions (< 1 DA) at the 
final examination. In remaining 11 eyes, however, final area of the lesion was greater 15 
than 1 DA, although the lesion remained relatively small and visual prognosis was often 
good. If these eyes had been examined later, they might be classified as having larger 
PCV. However, despite these shortcomings, our findings suggest that most smaller PCV 
show limited progression and that good visual function is maintained—with no serious 
complications. Furthermore, it may be of use to differentiate this type of PCV from larger 20 
PCV in order to prognosticate visual prognosis in affected individuals. 
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Figure Captions 15 
Figure 1. Scattergrams showing area of the lesion, greatest linear dimension, foveal 
thickness, and visual acuity (VA) in eyes with polypoidal choroidal vasculopathy (PCV) 
obtained at initial and final examinations. Initial area (upper left) is correlated significantly 
with final area of the lesion (R = 0.801, P < .0001). Initial greatest linear dimension 
(upper right) is correlated significantly with final greatest linear dimension (R = 0.805, P 20 
< .0001). Correlations between initial and final foveal thickness (bottom left) (R = 0.316, 
P = .0025), and initial and final VA (bottom right) (R = 0.355, P = .0006). VA measured 
with a Landolt chart was converted to a logarithm of the minimal angle of resolution 
(logMAR).   
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polypoidal choroidal vasculopathy (PCV). All eyes showed the branching vascular 
network that terminated in a polypoidal lesion, although the lesions varied in size. 
(Upper) Indocyanine green angiograms in the group with smaller PCV. (Bottom) 
Indocyanine green angiograms in the group with larger PCV. 
 5 
Figure 3. Progression of the vascular lesion in larger polypoidal choroidal vasculopathy 
(PCV). (Upper left) Fundus photograph at the initial visit shows a reddish orange nodule 
with a minute pigment epithelial detachment (PED). (Upper right) A sectional image 
obtained with optical coherence tomography (OCT) along with an arrow seen in the 
fundus photograph shows a small protrusion of the retinal pigment epithelium 10 
corresponding to the PED. (2nd row, left) Fluorescein angiography at the initial visit 
shows occult choroidal neovascularization corresponding to a branching vascular 
network. (2nd row, right) Indocyanine green angiography reveals large vascular 
components of PCV, consisting of a polypoidal lesion (arrow) and a branching vascular 
network (long arrow). The area of the PCV lesion was 5.87 mm2. (3rd row, left) In spite of 15 
three anti-VEGF treatments, the vascular lesion progressed. Fundus photograph 
obtained at 33 months after the initial visit shows a large serosanguineous PED. (3rd row, 
right) A sectional image obtained by OCT (with the arrow shown in the fundus 
photograph) shows a steep protrusion of retinal pigment epithelium, which is reflective of 
the large PED. (Bottom left) Fluorescein angiography shows occult choroidal 20 
neovascularization corresponding to the branching vascular network. (Bottom right) 
indocyanine green angiography shows progression of the polypoidal lesions and 
extension of the branching vascular network. The area of the PCV lesion increased to 
9.40 mm2.  
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vasculopathy (PCV). (Upper left) Fundus photograph at the initial visit shows a small 
reddish orange nodule (arrow); vision was 20/16. (Upper middle) Fluorescein 
angiography (FA) at the initial visit shows only a hyperfluorescent spot corresponding to 
the polypoidal lesion. (Upper right) Indocyanine green angiography shows the vascular 
components of PCV, which consist of a typical polypoidal lesion (arrow) and a branching 5 
vascular network (long arrow). The baseline area of the PCV lesion was 1.77 mm2. (2nd 
row) A sectional image obtained with optical coherence tomography (OCT) along with 
the arrow seen in the FA image shows a steep protrusion of the retinal pigment 
epithelium. (3rd row, left) No treatment was performed. Fundus photograph obtained at 
39 months after the initial visit shows a reddish orange nodule with a newly developed 10 
serous pigment epithelial detachment; vision was still 20/13. (3rd row, middle) FA shows 
a hyperfluorescent spot that corresponds to the polypoidal lesion, along with fluorescein 
pooling in the pigment epithelial detachment. (3rd row, right) Indocyanine green 
angiography reveals no progression of the vascular lesion of PCV. (Bottom) A sectional 
image obtained with OCT (with the arrow seen on FA) shows protrusion of the retinal 15 
pigment epithelium that corresponds to the branching network (arrowheads) and steep 
elevation of the retinal pigment epithelium with moderate inner reflectivity (arrow) 
corresponding to the polypoidal lesion. 
 
Figure 5. Suprachoroidal hemorrhage and vitreous hemorrhage in an eye with larger 20 
polypoidal choroidal vasculopathy (PCV). (Upper) Fundus photograph at the initial visit 
shows multiple large reddish orange nodules; vision was 20/22. Indocyanine green 
angiography shows a large branching vascular network that terminates with multiple 
polypoidal lesions. The baseline area of the PCV lesion was 15.80 mm2. (Middle) No 
treatment was performed because this eye had good visual acuity. Fundus photograph 25 
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components; vision was 20/16. Indocyanine green angiography shows some extension 
of the vascular lesion of PCV. (Bottom) Five months after the last angiogram, the eye 
developed a sudden suprachoroidal hemorrhage with subsequent vitreous hemorrhage. 
After vitreous surgery, visual acuity in this eye was only 20/200. 





















Gender (women/men) 28/60 8/14 20/46 .5971 
Age (years) 70.4 ± 7.5 68.2 ± 6.9 70.8 ± 7.7 .3257 
Hypertension 38 11 27 .4560 
Smoking 14 4 10 .7365 










Duration of symptoms (months) 8.0 ± 11.9 7.0 ± 9.5 8.3 ± 12.6 .6484 
Initial conditions     
    Best-corrected visual acuity (logMAR) 0.37 ± 0.34 0.24 ± 0.29 0.42 ± 0.35 .0383 
    Area of lesion (mm
2
) 7.75 ± 9.78 1.68 ± 0.53 9.79 ± 10.55 .0006 
    Greatest linear dimension (µm) 3412 ± 1647 1901 ± 464 3915 ± 1591 <.0001 
    Foveal thickness (µm) 403.5 ± 189.9 377.6 ± 175.4 412.2 ± 195.0 .4628 
Thickness of neurosensory retina in the 
fovea (µm) 
 
196.5 ± 83.8 
 
209.1 ± 98.5 
 
192.4 ± 78.6 
 
.4204 
     
Follow-up period (months) 46.4 ± 8.1 44.5 ± 6.7 47.0 ± 8.4 .2020 
Treatment     
    Photodynamic therapy 69 16 53 .3055 
        (Times of treatments) 1.9 ± 1.1 1.5 ± 0.7 2.1 ± 1.2 .0875 
    Anti-VEGF therapy 40 6 34 .0480 
        (Times of treatments) 2.9 ± 2.5 3.8 ± 3.7 2.7 ± 2.2 .3155 
    Pars plana vitrectomy 4 0 4 .2372 
    Cataract surgery 8 3 5 .2554 
     
Final conditions     
    Best-corrected visual acuity (logMAR) 0.62 ± 0.51 0.19 ± 0.33 0.76 ± 0.49 <.0001 
    Area of lesion (mm
2
) 13.24 ± 13.47 4.13 ± 3.59 16.27 ± 14.19 .0002 
    Greatest linear dimension (µm) 4511 ± 2030 2761 ± 900 5095 ± 1967 <.0001 
    Foveal thickness (µm) 299.7 ± 189.5 235.3 ± 65.1 321.2 ± 211.7 .0651 
Thickness of neurosensory retina in the 
fovea (µm) 
 
197.1 ± 168.1 
 
153.3 ± 38.4 
 
211.7 ± 191.1 
 
.1597 
     
Changes during follow-up     
    Best-corrected visual acuity (logMAR) 0.24 ± 0.51 -0.05 ± 0.36 0.34 ± 0.51 .0015 
    Area of lesion (mm
2
) 5.48 ± 8.13 2.45 ± 3.53 6.49 ± 8.96 .0429 
Table 1.
     Greatest linear dimension (µm) 1100 ± 1204 860 ± 933 1180 ± 1278 .2838 
    Foveal thickness (µm) -103.8 ± 221.9 -142.3 ± 163.6 -91.0 ± 237.8 .3500 
Thickness of neurosensory retina in the 
fovea (µm) 
 
0.6 ± 168.0 
 
-55.8 ± 103.3 
 
19.3 ± 181.4 
 
.0691 
n = number; logMAR = logarithm of the minimum angle of resolution; VEGF = vascular endothelial growth factor. 
One disc area (DA) is estimated as 2.54 mm
2
 on the basis of the one optic disc diameter of 1.8 mm. Based on the 
area of lesion at the initial visit, polypoidal choroidal vasculopathy (PCV) eyes were divided into smaller PCV (area 
of lesion < 1 DA) and larger PCV (area of lesion > 1 DA). 
  
TABLE 2.  Ocular Manifestations and Complications Seen in Eyes with Polypoidal Choroidal 





















Suprachoroidal hemorrhage 7 0 7 .1113 
Vitreous hemorrhage 8 0 8 .0868 
Recurrence 56 11 44 .1620 
Type 2 choroidal neovascularization 26 1 25 .0030 
Fibrosis 31 4 27 .0533 
Serous retinal detachment 81 20 65 .0899 
Subretinal hemorrhage (> 1DA) 55 9 46 .0157 
Cystoid macula edema 42 6 36 .0266 
Pigment epithelial detachment (> 1DA) 41 5 36 .0096 
Tear of retinal pigment epithelium 8 0 8 .0868 
n = number; DA = disc area. 
One disc area (DA) is estimated as 2.54 mm2 on the basis of one optic disc diameter being 1.8 mm.  
Based on the area of the lesion at the initial visit, polypoidal choroidal vasculopathy (PCV) eyes were 
divided into smaller PCV (area of lesion < 1 DA) and larger PCV (area of lesion > 1 DA). 
Table 2.
 TABLE 3.  ARMS2 Genotypes and Alleles in Patients with Polypoidal Choroidal 
Vasculopathy 
 
 Smaller Polypoidal 
Choroidal 
Vasculopathy 












Odds Ratio (95%CI) 
Genotype   .0397  
TT 3 (10.7%) 25 (89.3%)  5.0 vs GG (3.93-6.44) 
GT 11 (39.3%) 17 (60.7%)  1.5 vs GG (1.19-1.82) 
GG 7 (35.0%) 13 (65.0%)   
     
Allele   .0235  
T 17 (20.2%) 67 (79.8%)  2.4 vs G (2.09-2.67) 
G 25 (36.8%) 43 (63.2%)   
CI = confidence interval; G = guanine; T = thymine. *Chi-square test. 
One disc area (DA) is estimated as being 2.54 mm2; this is based on one optic disc 
diameter being 1.8 mm. Based on the area of the lesion at the initial visit, polypoidal 
choroidal vasculopathy (PCV) eyes were divided into smaller PCV (area of lesion < 1 DA) 
and larger PCV (area of lesion > 1 DA). 
Table 3.
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
